Loading...
•
Mar 31, 2022
AdaptHealth Q1 2022 Earnings Report
Announced first quarter 2022 results and updated 2022 guidance, along with a $200 million share repurchase program.
Key Takeaways
AdaptHealth reported strong first-quarter results, driven by continued strength in the diabetes product line and resilient HME product line. The company is updating its previously issued financial guidance for fiscal year 2022 and announced the authorization of a share repurchase program for up to $200 million.
Saw continued strength in diabetes product line, consistent with expectations.
HME product line continues to be resilient as CPAP patient set ups in March and April were at or near 2021 levels.
Operating and financial results demonstrate the Company’s strong position as a leading national provider of medical equipment and supplies across the U.S.
Announced a $200 million share repurchase program, reflecting confidence in AdaptHealth’s outlook.
Forward Guidance
AdaptHealth updated its previously issued financial guidance for fiscal year 2022, based on current business, market trends, governmental reimbursement updates, and acquisitions to date. Guidance for fiscal year 2022 does not include any contribution from acquisitions that have not yet closed, or continuing Public Health Emergency benefits beyond the currently scheduled expiration date.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...